-
1 Comment
From a valuation standpoint, the stock is 648.8% more expensive than other stocks from the sector with a price to sales ratio of 301.1.
Based on the above factors, New Horizon Health Limited gets an overall score of 0/5.
| Exchange | HK |
|---|---|
| CurrencyCode | HKD |
| ISIN | KYG6485S1021 |
| Sector | Healthcare |
| Industry | Medical Devices |
| PE Ratio | None |
|---|---|
| Target Price | 46.18 |
| Beta | 1.26 |
| Market Cap | 6B |
| Dividend Yield | None |
New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2015 and is headquartered in Hangzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 6606.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
